产品
编 号：F625963
分子式：C19H26F3N3O3
分子量：401.42
分子式：C19H26F3N3O3
分子量：401.42
产品类型
规格
价格
是否有货
结构图
CAS No: 1222102-29-5
产品详情
生物活性：
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
体内研究：
Evogliptin (100, 300 mg/kg; in animal feedings; single daily for 10 weeks) exhibits antidiabetic effects on HFD/STZ mice and improves glucose intolerance and insulin resistance.Animal Model:Male ICR mice (four-week-old; HFD/STZ mice model).
Dosage:100, 300 mg/kg
Administration:In animal feedings; single daily for 10 weeks
Result:Decreased the blood glucose level from the second weekand persisted through the 10-week treatment, when at 300 mg/kg.Significantly reduced HbA1c level when dosage at 300 mg/kg.Significantly decreased 6 h-fasted blood glucose levels in a dose-dependent manner.
体外研究：
Evogliptin (2.49 mM; 12 h) efficiently inhibits mDPP4 (membrane DPP4) enzymatic activity in PWM-induced H9 Th1 cells.Evogliptin prevents inflammatory and fibrotic signaling through autophagy induction in primary hepatocytes of ATG7f/f-Cre+ mice.
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
体内研究：
Evogliptin (100, 300 mg/kg; in animal feedings; single daily for 10 weeks) exhibits antidiabetic effects on HFD/STZ mice and improves glucose intolerance and insulin resistance.Animal Model:Male ICR mice (four-week-old; HFD/STZ mice model).
Dosage:100, 300 mg/kg
Administration:In animal feedings; single daily for 10 weeks
Result:Decreased the blood glucose level from the second weekand persisted through the 10-week treatment, when at 300 mg/kg.Significantly reduced HbA1c level when dosage at 300 mg/kg.Significantly decreased 6 h-fasted blood glucose levels in a dose-dependent manner.
体外研究：
Evogliptin (2.49 mM; 12 h) efficiently inhibits mDPP4 (membrane DPP4) enzymatic activity in PWM-induced H9 Th1 cells.Evogliptin prevents inflammatory and fibrotic signaling through autophagy induction in primary hepatocytes of ATG7f/f-Cre+ mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备